查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
腫瘤生物學名藥市場與 COVID-19 影響分析，按藥物類別、癌症類型、配銷通路、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1339905

腫瘤生物學名藥市場與 COVID-19 影響分析，按藥物類別、癌症類型、配銷通路、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Oncology Biosimilars Market with COVID-19 Impact Analysis, By Drug Class, By Type of Cancer, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 302 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年腫瘤生物學名藥市場規模為420012萬美元，2023年至2030年年複合成長率為10.67%。

腫瘤生物學名藥市場-市場動態：

  • 癌症患病率增加。
  • 癌症發病率的上升是推動腫瘤生物學名藥市場的主要因素。國際癌症研究機構 (IARC) 預測，到 2040 年，全球將有 1630 萬人死於癌症，新診斷癌症人數將達到 2750 萬人。正常細胞經歷一個多階段的過程，通常從癌前病變到癌症開始時的惡性腫瘤。除了正常的風險積累之外，老年人的細胞修復系統通常效率較低。吸煙、飲酒、不良飲食、缺乏運動以及空氣污染都會增加患癌症的風險。

腫瘤生物學名藥市場 - 主要見解：

  • 根據我們的研究分析師分享的分析，全球腫瘤生物學名藥市場預計在預測期內（2023-2030）每年將以 10.67% 左右的年複合成長率成長
  • 由於癌症患病率不斷上升，腫瘤生物學名藥行業預計將以顯著的速度成長
  • 根據藥物類別細分，預計 G-CSF 將在 2022 年呈現最大市場佔有率
  • 根據癌症類型，乳腺癌是 2022 年的主要癌症類型
  • 從配銷通路細分來看，2022年醫院零售為主導類型
  • 按地區分類，北美是 2022 年的主要收入來源

腫瘤生物學名藥市場-細分分析：

  • 全球腫瘤生物學名藥市場根據藥物類別、癌症類型、配銷通路和地區進行細分。
  • 市場根據藥物類別分為幾類：單克隆抗體、G-CSF、造血劑等。 G-CSF 較高的市場佔有率是化療後廣泛使用 G-CSF 來幫助癌症治療後白細胞恢復的結果。粒細胞集落刺激因子 (G-CSF) 有多種形式，包括非格司亭、來格司亭、長效非格司亭和聚乙二醇非格司亭。
  • 市場根據癌症類型分為幾類：乳腺癌、肺癌、胃癌、前列腺癌、宮頸癌、血癌、腦癌等。由於乳腺癌病例在全球所有惡性腫瘤中所佔比例最高，因此乳腺癌行業佔據了市場主導地位。許多變量都會增加患乳腺癌的風險，包括年齡、肥胖、酗酒、吸煙、絕經後激素治療、輻射史和疾病家族史。

腫瘤生物學名藥市場 - 地理洞察：

從地域上看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區以及中東和非洲地區。這些區域根據開展業務的國家進一步分類。亞太地區是一個發展中市場，尤其是韓國、中國和印度，在癌症生物學名藥方面取得了長足的進步。由於人口眾多，健康意識不斷增強，醫療保健支出不斷增加，製造成本下降，也反映了市場未來的潛力。

腫瘤生物學名藥市場-競爭格局：

公司通過多種管道銷售產品，包括企業網站、電子商務網站、零售商、分銷商和最終消費者。產品製造商在多個方面進行競爭，包括產品成本、性能、產品製造、配銷通路、聲譽和可用性。企業用來擴大影響力和擴大市場佔有率的一些主要技術包括新產品發布、分銷網路開發、研發支出以及併購。例如，2022 年 5 月，Biocon Biologics 和 Viatris 生產的第三種癌症生物學名藥 Abevmy（貝伐珠單抗）已在加拿大上市。

最近的發展：

2022 年 9 月，Celltrion USA 獲得 FDA 許可，使用其腫瘤生物學名藥 vegzelma (bevacizumab-add) 治療六種不同形式的癌症。

該研究的主要特點：

  • 這項關於腫瘤生物學名藥市場的擬議研究提供了市場規模（百萬美元）、年複合成長率（CAGR%）和預測估計（2023-2030），以 2022 年為基準年
  • 該報告為客戶提供有關腫瘤生物學名藥市場的最新趨勢見解。
  • 該研究報告闡明了不同細分市場/國家的潛在成長機會，並解釋了腫瘤生物學名藥市場有吸引力的投資主張矩陣
  • 總體報告確定了新的投資機會、老牌參與者面臨的挑戰以及腫瘤生物學名藥市場維持的成長因素
  • COVID-19 對腫瘤生物學名藥市場規模、預測、年複合成長率和市場動態的影響將在研究範圍下詳細討論。還將涵蓋對新冠疫情后腫瘤生物學名藥市場的詳細見解。
  • 為了讓本報告的用戶全面了解腫瘤生物學名藥市場，我們還對腫瘤生物學名藥市場的競爭格局和關鍵創新者進行了分析。
  • 該研究包括成長前景映射分析，其中所有行業細分都根據其市場規模、成長率和吸引力進行基準測試。
  • 該報告提供了主要市場參與者的詳細公司概況，這將幫助用戶了解在腫瘤生物學名藥市場營運的參與者的財務資訊和戰略舉措。
  • 此外，報告還揭示了全球和區域市場主要參與者的重要收購和兼併、合作和合資、新產品推出、研發、區域擴張。
  • 全球腫瘤生物學名藥市場報告主要面向該行業的各個利益相關者，包括供應商、投資者、新進入者、分銷商和財務分析師

目錄

第 1 章：腫瘤生物學名藥市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按藥物類別分類的腫瘤生物學名藥市場片段
    • 按癌症類型分類的腫瘤生物學名藥市場片段
    • 按配銷通路分類的腫瘤生物學名藥市場片段
    • 按國家/地區分類的腫瘤生物學名藥市場摘要
    • 按地區分類的腫瘤生物學名藥市場片段
  • 競爭洞察

第 3 章：腫瘤生物學名藥主要市場趨勢

  • 腫瘤生物學名藥市場促進因素
    • 市場促進因素的影響分析
  • 腫瘤生物學名藥市場限制
    • 市場限制影響分析
  • 腫瘤生物學名藥市場機遇
  • 腫瘤生物學名藥市場未來趨勢

第 4 章：腫瘤生物學名藥行業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：腫瘤生物學名藥市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的細分市場
    • 邊際成長部分
    • 最鬆散的部分
    • 邊際損失部分

第 6 章：腫瘤生物學名藥市場格局

  • 2022 年腫瘤生物學名藥市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既定玩家分析
    • 新興玩家分析

第 7 章：腫瘤生物學名藥市場 - 按藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 單克隆抗體
    • 粒細胞集落刺激因子
    • 造血劑
    • 其他

第 8 章：腫瘤生物學名藥市場 - 按癌症類型

  • 概述
    • 按癌症類型分類的細分市場佔有率分析
    • 乳癌
    • 肺癌
    • 胃癌
    • 前列腺癌
    • 宮頸癌
    • 血癌
    • 腦癌
    • 其他

第 9 章：腫瘤生物學名藥市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 零售藥店
    • 醫院藥房
    • 網上藥店

第 10 章：腫瘤生物學名藥市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美
    • 概述
    • 北美腫瘤生物學名藥主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模和預測（按癌症類型）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲腫瘤生物學名藥主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模和預測（按癌症類型）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區腫瘤生物學名藥主要製造商
    • 亞太地區市場規模和預測（按國家）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模和預測（按癌症類型）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳大利亞
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲腫瘤生物學名藥主要製造商
    • 拉丁美洲市場規模和預測（按國家）
    • 拉丁美洲市場規模和預測（按藥物類別）
    • 拉丁美洲市場規模和預測（按癌症類型）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 腫瘤生物學名藥中東和非洲的主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（按癌症類型）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 火雞
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 腫瘤生物學名藥行業

  • 競爭儀表板
  • 公司簡介
    • Teva Pharmaceuticals
    • STADA Arzneimittel AG
    • Shanghai Henlius Biotech
    • Sandoz (Novartis)
    • Samsung Bioepis
    • Pfizer
    • Pfenex Inc.
    • Mylan
    • Innovent Biologics
    • Dr. Reddy's Laboratories
    • Celltrion Healthcare
    • Biocon
    • Apotex
    • Amgen
    • Accord Healthcare

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯繫我們
Product Code: ANV1629

REPORT HIGHLIGHT

Oncology Biosimilars Market size was valued at USD 4,200.12 Million in 2022, expanding at a CAGR of 10.67% from 2023 to 2030.

Oncology biosimilars are biological medicines created to be strikingly comparable to and functionally equal to the oncology reference biologics, which are currently available in pharmaceuticals. These biosimilars are created to offer affordable cancer therapy choices. They go through thorough comparative tests to show that they are comparable in terms of safety, quality, and efficacy. Oncology biosimilars seek to improve patient access to essential cancer treatments while also perhaps lowering healthcare costs by providing therapeutic results that are equivalent to those of the unique oncology biologics. A comprehensive regulatory review is required for their approval to guarantee patient safety and maintain cancer treatment requirements.

Oncology Biosimilars Market- Market Dynamics:

  • Increasing prevalence of cancer.
  • The rising incidence of cancer is the primary factor driving the market for oncology biosimilars. The International Agency for Research on Cancer (IARC) predicts that by 2040, there would be 16.3 million cancer-related deaths globally and 27.5 million new cancer diagnoses. Normal cells go through a multi-stage process that normally goes from a pre-cancerous lesions to a tumor that is malignant when cancer begins. Aging persons often have less effective cellular repair systems in addition to the normal risk buildup. Smoking, consuming alcohol, adopting a poor diet, leading a life of inactivity, and air pollution all increase the chance of developing cancer.

Oncology Biosimilars Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Oncology Biosimilars market is estimated to grow annually at a CAGR of around 10.67% over the forecast period (2023-2030)
  • The Oncology Biosimilars industry is projected to grow at a significant rate due to the growing prevalence of cancer
  • Based on drug class segmentation, G-CSF was predicted to show maximum market share in the year 2022
  • Based on type of cancer, breast cancer was the leading type in 2022
  • Based on distribution channel segmentation, hospital retail was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Oncology Biosimilars Market- Segmentation Analysis:

  • The Global Oncology Biosimilars Market is segmented on the basis of Drug Class, Type of Cancer, Distribution Channel, and Region.
  • The market is divided into categories based on Drug Class: monoclonal antibodies, G-CSF, hematopoietic agents, and others. The higher market share of G-CSF is a result of the widespread use of G-CSF after chemotherapy to aid in the recovery of white blood cells following cancer treatment. Granulocyte colony-stimulating factors (G-CSF) are available in a variety of forms, including filgrastim, lenograstim, long-acting filgrastim, and pegfilgrastim.
  • The market is divided into categories based on type of cancer: breast cancer, lung cancer, stomach cancer, prostate cancer, cervical cancer, blood cancer, brain cancer, and others. Due to the highest percentage of breast cancer cases globally among all malignancies, the breast cancer sector commands the market. The risk of breast cancer is increased by a number of variables, including age, obesity, alcoholism, cigarette use, postmenopausal hormone treatment, exposure to radiation history, and family history of the disease.

Oncology Biosimilars Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The Asia Pacific region is a developing market, with Korea, China, and India, in particular, making strides with cancer biosimilars. Due to a large population, rising health consciousness, rising healthcare expenditure, and decreased manufacturing costs, they also reflect the market's future potential.

Oncology Biosimilars Market- Competitive Landscape:

Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of aspects, including product costs, performance, product making, Distribution Channel, reputation, and availability. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, May 2022, Abevmy (bevacizumab), the third cancer biosimilar produced by Biocon Biologics and Viatris, has made accessible in Canada.

Recent Developments:

September 2022, Celltrion USA received FDA permission for using its oncology biosimilar vegzelma (bevacizumab-add) to treat six different forms of cancer.

Key features of the study:

  • This proposed research study on Oncology Biosimilars market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Oncology Biosimilars market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Oncology Biosimilars market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Oncology Biosimilars market
  • Impact of COVID-19 on Oncology Biosimilars market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Oncology Biosimilars market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Oncology Biosimilars market, we have also included competitive landscape and key innovator analysis for the Oncology Biosimilars market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Oncology Biosimilars market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Oncology Biosimilars market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ONCOLOGY BIOSIMILARS MARKET KEY PLAYERS

  • Teva Pharmaceuticals
  • STADA Arzneimittel AG
  • Shanghai Henlius Biotech
  • Sandoz (Novartis)
  • Samsung Bioepis
  • Pfizer
  • Pfenex Inc.
  • Mylan
  • Innovent Biologics
  • Dr. Reddy's Laboratories
  • Celltrion Healthcare
  • Biocon
  • Apotex
  • Amgen
  • Accord Healthcare

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DRUG CLASS

  • Monoclonal Antibodies
  • G-CSF
  • Hematopoietic Agents
  • Others

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY TYPE OF CANCER

  • Breast Cancer
  • Lung Cancer
  • Stomach Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Blood Cancer
  • Brain Cancer
  • Others

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Oncology Biosimilars Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Oncology Biosimilars Market Snippet by Drug Class
    • 2.1.2. Oncology Biosimilars Market Snippet by Type of Cancer
    • 2.1.3. Oncology Biosimilars Market Snippet by Distribution Channel
    • 2.1.4. Oncology Biosimilars Market Snippet by Country
    • 2.1.5. Oncology Biosimilars Market Snippet by Region
  • 2.2. Competitive Insights

3. Oncology Biosimilars Key Market Trends

  • 3.1. Oncology Biosimilars Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Oncology Biosimilars Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Oncology Biosimilars Market Opportunities
  • 3.4. Oncology Biosimilars Market Future Trends

4. Oncology Biosimilars Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Oncology Biosimilars Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Oncology Biosimilars Market Landscape

  • 6.1. Oncology Biosimilars Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Oncology Biosimilars Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 7.1.2. Monoclonal Antibodies
    • 7.1.3. G-CSF
    • 7.1.4. Hematopoietic Agents
    • 7.1.5. Others

8. Oncology Biosimilars Market - By Type of Cancer

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type of Cancer, 2022 & 2030 (%)
    • 8.1.2. Breast Cancer
    • 8.1.3. Lung Cancer
    • 8.1.4. Stomach Cancer
    • 8.1.5. Prostate Cancer
    • 8.1.6. Cervical Cancer
    • 8.1.7. Blood Cancer
    • 8.1.8. Brain Cancer
    • 8.1.9. Others

9. Oncology Biosimilars Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Retail Pharmacies
    • 9.1.3. Hospital Pharmacies
    • 9.1.4. Online Pharmacies

10. Oncology Biosimilars Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Oncology Biosimilars Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Oncology Biosimilars Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Oncology Biosimilars Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Oncology Biosimilars Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Oncology Biosimilars Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Oncology Biosimilars Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Teva Pharmaceuticals
    • 11.2.2. STADA Arzneimittel AG
    • 11.2.3. Shanghai Henlius Biotech
    • 11.2.4. Sandoz (Novartis)
    • 11.2.5. Samsung Bioepis
    • 11.2.6. Pfizer
    • 11.2.7. Pfenex Inc.
    • 11.2.8. Mylan
    • 11.2.9. Innovent Biologics
    • 11.2.10. Dr. Reddy's Laboratories
    • 11.2.11. Celltrion Healthcare
    • 11.2.12. Biocon
    • 11.2.13. Apotex
    • 11.2.14. Amgen
    • 11.2.15. Accord Healthcare

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Oncology Biosimilars Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Oncology Biosimilars Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Oncology Biosimilars Market: Type of Cancer Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type of Cancer
  • TABLE Global Oncology Biosimilars Market, by Type of Cancer 2018-2030 (USD Million)
  • TABLE Oncology Biosimilars Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Oncology Biosimilars Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Oncology Biosimilars Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Oncology Biosimilars Market, by Region 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)

List of Figures

  • FIGURE Oncology Biosimilars Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Drug Class segment market share analysis, 2022 & 2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Type of Cancer segment market share analysis, 2022 & 2030
  • FIGURE Type of Cancer segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2022 & 2030
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Europe Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Asia Pacific Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Latin America Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Middle East and Africa Oncology Biosimilars Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE Germany Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE India Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE Brazil Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE Saudi Arabia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)